Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with type 2 diabetes, metabolic syndrome, obesity, or high blood pressure — based on the specific measurements described below — or who are already receiving treatment for one of these conditions.
- People with type 2 diabetes, which the trial defines as: two or more fasting blood sugar readings above 7.0 mmol/L, OR a blood sugar above 11.1 mmol/L two hours after a glucose drink test, OR an HbA1c result of 48 mmol/mol (6.5%) or higher, OR currently being treated for type 2 diabetes by a doctor.
- People with obesity, which the trial defines as: a Body Mass Index (BMI) over 30, OR a waist measurement above certain thresholds depending on background (for example, Caucasian males ≥94 cm, Caucasian females ≥80 cm — confirm exact thresholds for other ethnic backgrounds with the trial site).
- People with high blood pressure, which the trial defines as: a top blood pressure reading of 140 mmHg or more, and/or a bottom reading of 90 mmHg or more, OR currently being treated for high blood pressure by a doctor.
- People with metabolic syndrome, which the trial defines as: excess abdominal weight (or BMI over 30), PLUS any two of the following — high triglycerides, low HDL ("good") cholesterol, raised blood pressure (top reading ≥130 or bottom ≥85 mmHg), or raised fasting blood sugar (≥5.6 mmol/L), or treatment for any of these conditions.
Who may not be able to join:
- People who have been diagnosed with hepatitis B, hepatitis C, HIV, or any other liver condition such as hemochromatosis, sarcoidosis, or Wilson's disease.
- People who have any other condition known to cause liver scarring or cirrhosis.
- People who drink more than 3 standard alcoholic drinks per day (males) or more than 2 standard alcoholic drinks per day (females).
- People who have any other significant medical condition or upcoming procedure that the trial doctor believes could affect their safety or participation in the study.
- People who are employees, contractors, or family members of staff involved in running the trial or the sponsoring organisation.
- People who are unable to understand the details of the trial or are unable to give written consent to participate.
- People who are currently pregnant or breastfeeding.
- People who had weight-loss (bariatric) surgery within the past 12 months.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Manuel Castro Cabezas, MD/PhD, Sint Franciscus Gasthuis
Phone: +31628259968
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk; Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk; Prevalence of at-risk MASH estimated by FAST score in patients at risk; *Subset of patients: prevalence of MASH in patients at risk; Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries; Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.